返回
Checkpoint Blockade
DOI:10.1158/2643-3230.BCD-21-0130.png)
摘要
En 中文
An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity.
期刊
IF:
11.5
论文数:
216
被引数:
1.7K
机构
引用论文
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
LEUKEMIA
IF13.4
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
BLOOD ADVANCES
IF7.1
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies联合anti-CTLA-4加anti-PD-1检查点阻断利用与单一疗法部分不同的细胞机制
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
BLOOD CANCER DISCOVERY
IF11.5
没有更多内容

